Skip navigation

Prospera Heart

Greater Confidence with Prospera

A single, noninvasive dd-cfDNA blood test for heart transplant monitoring. Early insight into active rejection risk may change everything.

Prospera works

Prospera – the next generation

  • Developed by Natera, a leader in cell-free DNA (cfDNA) with a trusted legacy in fetal monitoring, oncology and organ health
  • Demonstrated in over 3 million tests1
  • Utilizes over 13,000 pan-ethnic SNPs and advanced bioinformatics2
  • Optimized to be the most precise cfDNA tool for early, clinically meaningful rejection assessment.3,4

Why Prospera?

The current surveillance landscape has limitations and the management of heart transplant recipients is complex and challenging

s2 graphic 1 acute rejection

25% of heart transplant recipients experience acute rejection in their first year5

Survival rates

Survival rates of heart transplant recipients show little improvement over time6

Endomyocardial biopsy (EMB)

Though endomyocardial biopsy (EMB) is the gold standard in surveillance for acute rejection, it has recognized challenges

“There is a need for a sensitive, noninvasive surveillance tool for early detection of transplant injury to reduce frequency of biopsy in heart transplantation.”3

Patients first, partners always

Natera’s suite of solutions allows for streamlined process integration for your center

Total EMRSync

Total EMRSync

A complete, secure bi-directional data and workflow interface with Epic and Cerner systems

  • Allows for easy ordering and delivery of results
ProsperaLink Program

ProsperaLink Program

A concierge team of clinical experts including a medical science liaison, nurse coordinator, & patient coordinator to help patients stay updated on blood draws, compliance plans and results.

Financial Support Program

Financial Support Program

  • Natera welcomes all insurances, and our goal is to make the process easy and transparent for patients
  • In the rare event your patient has financial responsibility, Natera offers flexible financial assistance programs and will work closely with your patient to ensure there is no hardship on them or their family.

Find out more about Prospera for heart transplant recipients

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time.


1Natera Inc. Natera validation data: manuscript submitted. Data on file.

2Sigdel TK, Archila FA, Constantin T, et al. Optimizing detection of kidney transplant injury by assessment of donor-derived cell-free DNA via massively multiplex PCR. J Clin Med. 2018 (per published article);8(1):19 doi:10.3390/jcm8010019

3Altug Y, Liang N, Ram R, et al. Analytical validation of a single-nucleotide polymorphism-based donor-derived cell-free DNA assay for detecting rejection in kidney transplant patients. Transplantation. 2019;103(12):2657-2665. doi:10.1097/TP.0000000000002665

4Grskovic M, Hiller DJ, Eubank LA, et al. Validation of a clinical-grade assay to measure donor-derived cell-free DNA in solid organ transplant recipients. J Mol Diagn. 2016;18(6):890-902 doi:10.1016/j. jmoldx.2016.07.0038.

5U.S. Department of Health & Human Services: Health Resources and Services Administration. Scientific Registry of Transplant Recipients (SRTR): Organ Procurement and Transplantation Network (OPTN)/SRTR 2019 Annual Data Report: Heart. Available at: aspx#HR_tx_adult_inc_AR_age_b64. Accessed June 1, 2021.

6Toyoda Y, Toyoda Y. Heart-lung transplantation: adult indications and outcomes. J Thorac Dis. 2014;6(8):1138-1142. doi:10.3978/j.issn.2072-1439.2014.06.01

icon-angle icon-bars icon-times